Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Bladder Dysfunction Reports
Published in: Current Bladder Dysfunction Reports 3/2017

01-09-2017 | Post-Prostatectomy and Acquired Voiding Dysfunction (V Tse, Section Editor)

Bulking Agents in the Management of Urinary Incontinence: Dead or Alive?

Published in: Current Bladder Dysfunction Reports | Issue 3/2017

Login to get access

Abstract

Purpose of Review

Although urethral bulking therapy has been available for more than 50 years, the ideal agent is still lacking and its result is considered inferior to surgery. In this review, we summarize the latest advances and evidences in the field of urethral bulking agents for treatment of stress urinary incontinence (SUI).

Recent Findings

The use of ultrasound evaluation post-urethral bulking provides insights for the optimal position and configuration of the bulking agent. Novel agents are available and show promising results in pre-clinical and clinical studies. More clinical data is available for currently available agent, e.g., Bulkamid. The field of cell-based urethral injection and regenerative medicine provides exciting future in treatment of SUI.

Summary

Urethral bulking therapy remains important in the treatment of SUI especially in high medical risk group or patients with recurrent SUI post-surgery. Further researches in novel bulking agents and regenerative medicine may further enhance its role and eliminate its current limitations.
Literature
1.
Kelly HA DW. Urinary incontinence in women without manifest injury to the bladder. Surg Gynecol Obstet. 1914:444–50.
2.
Murless BC. The injection treatment of stress incontinence. J Obstet Gynaecol Br Emp. 1938:67–73.
3.
4.
5.
Dmochowski RR, Appell RA. Injectable agents in the treatment of stress urinary incontinence in women: where are we now? Urology. 2000;56:32–40.CrossRefPubMed
6.
7.
Bent AE, Foote J, Siegel S, Faerber G, Chao R, Gormley EA. Collagen implant for treating stress urinary incontinence in women with urethral hypermobility. J Urol. 2001;166:1354–7.CrossRefPubMed
8.
9.
10.
• Hegde A, Smith AL, Aguilar VC, Davila GW. Three-dimensional endovaginal ultrasound examination following injection of Macroplastique for stress urinary incontinence: outcomes based on location and periurethral distribution of the bulking agent. Int Urogynecol J. 2013;24:1151–9. doi:10.​1007/​s00192-012-1983-9. This paper presented a large group of patients with their transvaginal ultrasound findings post-urethral bulking injection and suggested the optimal location of bulking agents. CrossRefPubMed
11.
12.
13.
Dmochowski R, Appell RA. Advancements in minimally invasive treatments for female stress urinary incontinence: radiofrequency and bulking agents. Curr Urol Rep. 2003;4:350–5.CrossRefPubMed
14.
Ghoniem G, Corcos J, Comiter C, Bernhard P, Westney OL, Herschorn S. Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study. J Urol. 2009;181:204–10. doi:10.​1016/​j.​juro.​2008.​09.​032.CrossRefPubMed
15.
16.
• Ghoniem GM, Miller CJ. A systematic review and meta-analysis of Macroplastique for treating female stress urinary incontinence. Int Urogynecol J. 2013;24:27–36. doi:10.​1007/​s00192-012-1825-9. This paper provided the pooled analysis of 20 years of researches on clinical use of Macroplastique. CrossRefPubMed
17.
18.
19.
Futyma K, Miotla P, Galczynski K, Baranowski W, Doniec J, Wodzislawska A, et al. An open multicenter study of clinical efficacy and safety of Urolastic, an injectable implant for the treatment of stress urinary incontinence: one-year observation. Biomed Res Int. 2015;2015:851823. doi:10.​1155/​2015/​851823.CrossRefPubMedPubMedCentral
20.
•• Futyma K, Nowakowski L, Galczynski K, Miotla P, Rechberger T. Nonabsorbable urethral bulking agent—clinical effectiveness and late complications rates in the treatment of recurrent stress urinary incontinence after 2 years of follow-up. Eur J Obstet Gynecol Reprod Biol. 2016;207:68–72. doi:10.​1016/​j.​ejogrb.​2016.​10.​011. This paper presented the largest series of patients using Urolastic in the recurrent SUI setting. CrossRefPubMed
21.
22.
Zivanovic I, Rautenberg O, Lobodasch K, von Bunau G, Walser C, Viereck V. Urethral bulking for recurrent stress urinary incontinence after midurethral sling failure. Neurourol Urodyn. 2016; doi:10.​1002/​nau.​23007.
23.
24.
Sebe P, Doucet C, Cornu J-N, Ciofu C, Costa P, de Medina SGD, et al. Intrasphincteric injections of autologous muscular cells in women with refractory stress urinary incontinence: a prospective study. Int Urogynecol J. 2011;22:183–9. doi:10.​1007/​s00192-010-1255-5.CrossRefPubMed
25.
Carr LK, Steele D, Steele S, Wagner D, Pruchnic R, Jankowski R, et al. 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:881–3. doi:10.​1007/​s00192-007-0553-z.CrossRefPubMed
26.
27.
Hakim L, Endo M, Feola A, Soebadi DM, Deprest J, de Ridder D, et al. High-frequency micro-ultrasound: a novel method to assess external urethral sphincter function in rats following simulated birth injury. Neurourol Urodyn. 2015;34:264–9. doi:10.​1002/​nau.​22555.CrossRefPubMed
28.
29.
30.
31.
32.
• Gras S, Klarskov N, Lose G. Intraurethral injection of autologous minced skeletal muscle: a simple surgical treatment for stress urinary incontinence. J Urol. 2014;192:850–5. doi:10.​1016/​j.​juro.​2014.​04.​005. This paper presented a novel, technically simple approach of cell therapy in treatment of SUI without the need of cell expansion or selection. CrossRefPubMed
33.
•• Mann-Gow TK, King BJ, El-Ghannam A, Knabe-Ducheyne C, Kida M, Dall OM, et al. Novel bioceramic urethral bulking agents elicit improved host tissue responses in a rat model. Adv Urol. 2016;2016:1282531. doi:10.​1155/​2016/​1282531. This paper studied two potential novel bioceramic bulking agents which showed larger bulking effects in animal models than existing agents. CrossRefPubMedPubMedCentral
34.
Mann-Gow TK, Blaivas JG, King BJ, El-Ghannam A, Knabe C, Lam MK, et al. Rat animal model for preclinical testing of microparticle urethral bulking agents. Int J Urol. 2015;22:416–20. doi:10.​1111/​iju.​12693.CrossRefPubMed
35.
Metadata
Title
Bulking Agents in the Management of Urinary Incontinence: Dead or Alive?
Publication date
01-09-2017
Published in
Current Bladder Dysfunction Reports / Issue 3/2017
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-017-0439-y

Other articles of this Issue 3/2017

Current Bladder Dysfunction Reports 3/2017 Go to the issue

Post-Prostatectomy and Acquired Voiding Dysfunction (V Tse, Section Editor)

Management of Patients with Concurrent Pelvic Organ Prolapse and Lower Urinary Tract Symptoms—Impact on Lower Urinary Tract Symptoms Following Prolapse Repair

Pediatric Bladder Dysfunction (SJ Hodges, Section Editor)

Endoscopic Treatment of Vesicoureteral Reflux

Pediatric Bladder Dysfunction (S Hodges, Section Editor)

Oral Medications in the Treatment of Bladder Overactivity

Pediatric Bladder Dysfunction (SJ Hodges, Section Editor)

Reliability and Reproducibility of Pediatric Urodynamic Studies

Pediatric Bladder Dysfunction (S Hodges, Section Editor)

Enema Regimen in Pediatric Bladder Dysfunction

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Intravesical Bacillus Calmette-Guerin Cystitis